Key facts
- This page summarizes Daniel R. Chevallard's Form 4 filing for LENZ Therapeutics, Inc. (LENZ).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Mar 2026, 08:46.
Daniel R. Chevallard - 27 Mar 2026 Form 4 Insider Report for LENZ Therapeutics, Inc. (LENZ)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- LENZ
- Reported as of
- 27 Mar 2026
- Net transaction value
- +$64,275
- SEC form
- 4
- Accepted by SEC
- 30 Mar 2026, 08:46:52 UTC
- Prior SEC filing
- 06 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel R. Chevallard
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Daniel R. Chevallard filed Form 4 for LENZ Therapeutics, Inc. (LENZ) on 30 Mar 2026.
Change
- Previous filing in this sequence was filed on 06 Jan 2026.
- Current net transaction value: +$64,275.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001706176
Primary reporting owner
Chevallard Daniel R.
- Relationship
- Chief Financial Officer
- Address
- C/O LENZ THERAPEUTICS, INC., 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
- Signature
- /s/ Daniel R. Chevallard
- Signature date
- 30 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LENZ
transaction
Common Stock
Purchase
- Transaction value
- $64,275
- Shares
- +7,500
- Change %
- +139%
- Price
- $8.57
- Shares after
- 12,886
- Date
- 27 Mar 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.